samedan logo
 
 
 
spacer
home > ebr > summer 2021 > innovation in oncology clinical trials
PUBLICATIONS
European Biopharmaceutical Review

Innovation in Oncology Clinical Trials

Until the 1990s, the understanding of tumour biology was largely descriptive in nature, and selectivity of oncology drugs was based largely on tumour cell characteristics, such as increased cell replication rate, capability to migrate and invade tissue, being able to evade recognition and destruction by the immune system, and capacity to evade normal mechanisms of senescence and apoptosis.

Traditional cancer therapy strategies centred around treating the tumour based on histological considerations and treating the entire patient population as an average. This ‘averaging’ of patients failed to effectively distinguish between patient subpopulations. Now, advances in genomics have ushered in a new era of precision medicine using methods to identify specific patient subpopulations based upon specific tumour lesions followed by utilisation of select lesion-specific targeted drug therapy.

This new era marks a shift from histology-based to lesion-based trial designs. This article explores how biomarker-based trial designs are reframing the clinical trial landscape and the latest FDA guidance on enrichment strategies for biomarker-based trial designs.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Brian Huber is a leader in the biopharmaceutical drug development, CRO service, and investment sectors, with over 35 years’ experience. His current position is the Vice President of Therapeutic Areas, Drug Development, and Consulting at ICON.

Dr Huber’s experiences include VP & Managing Director at Quintiles/IQVIA, Global VP in Drug Discovery at GSK, CEO of Shionogi/GW Pharmaceutical Inc., Director of Oncology at Burroughs Wellcome, and Senior Staff Fellow at the National Cancer Institute, NIH, in Bethesda, US. Dr Huber has 11 issued patents, 65 publications in peer-reviewed journals, and a number of books and book chapters.
spacer
Brian Huber
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases

MyMD Pharmaceuticals Inc., a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,085,047 titled “Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.”
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement